Zacks Analyst Blog Highlights: Tiffany, Big Lots, Family Dollar, Isis Pharmaceuticals and OncoGenex

http://www.profit.zacks.com/
CHICAGO--(Business Wire)--
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day
the Zacks Equity Research analysts discuss the latest news and events impacting
stocks and the financial markets. Stocks recently featured in the blog include:
Tiffany (NYSE: TIF), Big Lots (NYSE: BIG), Family Dollar (NYSE: FDO), Isis
Pharmaceuticals (Nasdaq: ISIS) and OncoGenex (Nasdaq: OGXI).

Get the most recent insight from Zacks Equity Research with the free Profit from
the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Tuesday`s Analyst Blog:

Long-Term Job Stagnation

The two major forces behind the secular slowdown in job creation have been
automation and globalization (off-shoring). It would not be particularly wise to
reverse job losses coming from automation, since technology is the source of
productivity growth and ultimately higher standards of living.

On the other hand, that model will not work to well if there are no jobs as a
result. What will happen is that there will be a further hollowing out of the
middle class, with a few extremely rich people and many who are struggling to
make ends meet, and a growing number in real poverty.

This suggests that we will have sort of a bar-bell economy -- with strong firms
that cater to the carriage trade, for example Tiffany`s (NYSE: TIF) and Neiman
Marcus, as well as inferior goods firms that do well such as Big Lots (NYSE:
BIG) and Family Dollar (NYSE: FDO). Firms in the middle will suffer.

Isis Generating Impressive Data

At perhaps the two biggest industry trade conferences of the year, the American
Society of Clinical Oncology (ASCO) and the American Diabetes Association (ADA),
Isis Pharmaceuticals (Nasdaq: ISIS) and/or its partners presented encouraging
pre-clinical and early-stage clinical data showing the potential power of
antisense technology as a new paradigm for treating cancer and diabetes -- two
of the most widespread diseases in the U.S. and worldwide.

Specifically, at the ASCO meeting in early June, Isis and/or its partners held 4
presentations on oncology candidates using Isis` technology. Specifically,
OncoGenex (Nasdaq: OGXI) presented data from 2 phase II programs with OGX-011
that demonstrated very encouraging data. In a phase II program, patients with
advanced metastatic prostate cancer were randomized to receive OGX-011 plus
docetaxel or docetaxel alone.

The median overall survival (OS) for the OGX-011 plus docetaxel group was 23.8
months, vs. 16.9 months with docetaxel alone. This corresponded to a 39%
reduction in the rate of death over the study period. OncoGenex hopes to secure
a partnership for OGX-011 and move into a phase III program shortly.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros
newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis
to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks.
Our analysts are organized by industry which gives them keen insights to
developments that affect company profits and stock performance. Recommendations
and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest
analysis from Zacks Equity Research. Subscribe to this free newsletter today:
http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in
1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns
in stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking system;
the Zacks Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations and market
insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of Profitable
ideas GUARANTEED to be worth your time! Register for your free subscription to
Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should
always research companies and securities before making any investments. Nothing
herein should be construed as an offer or solicitation to buy or sell any
security.

Zacks.com
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Copyright Business Wire 2009